Nurix to Present New NX-5948 Clinical Data at EHA2024

Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced new clinical data from its selective BTK degrader, NX-5948. This data will be presented at the European Hematology Association Congress, which is scheduled from June 13 - 16, 2024, in Madrid, Spain, and online.

The presentation will feature updated findings from an ongoing Phase 1a/b study of NX-5948 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. These patients are heavily pretreated and include those with resistance mutations to BTK inhibitors and central nervous system (CNS) involvement. As of January 2024, among the 10 evaluable CLL patients, the overall response rate was 70%. The responses have shown deepening with prolonged treatment and follow-up, and all responses were ongoing at the time of the data cut. Additional data, encompassing higher dose levels and extended treatment durations, will be unveiled at the EHA2024 in June.

The presentation details are as follows:
- Title: Latest results from an ongoing first-in-human Phase 1a/b study of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies.
- Session: s445 Novel therapies in relapsed and refractory CLL and hairy cell leukemia
- Session Date and Time: Sunday, June 16, 11:30 a.m. – 12:45 p.m. CEST
- Location: Hall Velasquez
- Presenter: Dr. Kim Linton
- Abstract #: S155

NX-5948 is an investigational, orally bioavailable small molecule that degrades Bruton’s tyrosine kinase (BTK). It is currently under evaluation in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies. NX-5948 has demonstrated high potency against a variety of tumor cell lines resistant to existing BTK inhibitor therapies, which is crucial for heavily pretreated CLL/SLL patient populations. More information on the clinical trial can be accessed at clinicaltrials.gov (NCT05131022).

Nurix Therapeutics is headquartered in San Francisco, California, and focuses on discovering, developing, and commercializing innovative therapies based on cellular protein level modulation. Their expertise in E3 ligases, combined with proprietary DNA-encoded libraries, has led to the development of DELigase, an integrated platform to identify and advance new drug candidates targeting E3 ligases. Nurix’s approach is to modulate the natural function of E3 ligases within the ubiquitin-proteasome system to selectively alter cellular protein levels. The company’s pipeline includes targeted protein degraders of BTK, crucial for B-cell signaling, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates immune cell activation.